Table 5 Most frequently reported treatment-emergent adverse events
From: Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL TM)
System organ class (SOC) | Stat. | Treatment | ||||
|---|---|---|---|---|---|---|
Preferred term | A | B | C | D | Overall | |
Number of subjects dosed | N | 21 | 16 | 18 | 15 | 24 |
Number of TEAEs | E | 21 | 16 | 18 | 15 | 24 |
Number of subjects with TEAEs | n (%) | 7 (33.3) | 4 (25.0) | 6 (33.3) | 6 (40.0) | 15 (62.5) |
Nervous system disorders | n (%) E | 5 (23.8) 6 | 4 (25.0) 4 | 3 (16.7) 3 | 2 (13.3) 2 | 11 (45.8) 15 |
Somnolence | n (%) E | 3 (14.3) 3 | 2 (12.5) 2 | 2 (11.1) 2 | 2 (13.3) 2 | 7 (29.2) 9 |
Headache | n (%) E | 3 (14.3) 3 | 2 (12.5) 2 | 0 | 0 | 5 (20.8) 5 |
Infections and infestations | n (%) E | 2 (9.5) 2 | 0 | 0 | 0 | 2 (8.3) 2 |
COVID-19 | n (%) E | 2 (9.5) 2 | 0 | 0 | 0 | 2 (8.3) 2 |